scholarly journals Nodal Melanoma Metastasis under Infliximab Therapy in a Patient with Nevoid Melanoma First Misdiagnosed as Benign Nevus: A Potentially Dangerous Diagnostic Pitfall in the Era of Biologic Therapies

2013 ◽  
Vol 5 (3) ◽  
pp. 290-294 ◽  
Author(s):  
Gilles Safa ◽  
Sophie Fromentoux ◽  
Laure Darrieux ◽  
Jean-Anastase Hogenhuis ◽  
Laurent Tisseau
Keyword(s):  
Infliximab Therapy ◽  
Melanoma Metastasis ◽  
Biologic Therapies ◽  
Benign Nevus ◽  
Diagnostic Pitfall

Melanoma metastasis to the breast: A diagnostic pitfall

2009 ◽  
Vol 32 (5-6) ◽  
pp. 458-461 ◽  
Author(s):  
Gulistan Bahat ◽  
Yasar Colak ◽  
Bulent Saka ◽  
Mehmet Akif Karan ◽  
Nesimi Buyukbabani
Keyword(s):  
Melanoma Metastasis ◽  
Diagnostic Pitfall

Improvement of bone metabolism after infliximab therapy in Crohn's disease

2004 ◽  
Vol 42 (05) ◽  
Author(s):  
P Miheller ◽  
G Mûzes ◽  
T Zágoni ◽  
M Tóth ◽  
Z Tulassay
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Bone Metabolism ◽  
Infliximab Therapy

Long-term management of resistant, fistulazing Crohn's disease by ongoing 4-weekly infliximab therapy (a case report)

2005 ◽  
Vol 43 (05) ◽  
Author(s):  
R Schwab ◽  
P Lakatos ◽  
E Schäfer ◽  
J Weltner ◽  
A Sáfrány ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Case Report ◽  
Crohn's Disease ◽  
Infliximab Therapy ◽  
Term Management

Prolonged survival of a patient with brain melanoma metastasis treated with BRAF and MEK inhibitors combination therapy

2020 ◽  
Vol 155 (2) ◽  
Author(s):  
Giulia Spallone ◽  
Virginia Garofalo ◽  
Eliseo Picchi ◽  
Rossella Pitocco ◽  
Federico Bianchi ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Prolonged Survival ◽  
Melanoma Metastasis ◽  
Mek Inhibitors

Applying personalized medicine to adult severe asthma

2021 ◽  
Vol 42 (1) ◽  
pp. e8-e16 ◽  
Author(s):  
Angelica Tiotiu
Keyword(s):  
Personalized Medicine ◽  
Severe Asthma ◽  
Negative Impact ◽  
Target Therapy ◽  
Asthma Management ◽  
Future Research ◽  
Biologic Therapies ◽  
Eosinophilic Asthma ◽  
Definition Of ◽  
Structured Approach

Background: Severe asthma is a heterogeneous disease that consists of various phenotypes driven by different pathways. Associated with significant morbidity, an important negative impact on the quality of life of patients, and increased health care costs, severe asthma represents a challenge for the clinician. With the introduction of various antibodies that target type 2 inflammation (T2) pathways, severe asthma therapy is gradually moving to a personalized medicine approach. Objective: The purpose of this review was to emphasize the important role of personalized medicine in adult severe asthma management. Methods: An extensive research was conducted in medical literature data bases by applying terms such as “severe asthma” associated with “structured approach,” “comorbidities,” “biomarkers,” “phenotypes/endotypes,” and “biologic therapies.” Results: The management of severe asthma starts with a structured approach to confirm the diagnosis, assess the adherence to medications and identify confounding factors and comorbidities. The definition of phenotypes or endotypes (phenotypes defined by mechanisms and identified through biomarkers) is an important step toward the use of personalized medicine in asthma. Severe allergic and nonallergic eosinophilic asthma are two defined T2 phenotypes for which there are efficacious targeted biologic therapies currently available. Non-T2 phenotype remains to be characterized, and less efficient target therapy exists. Conclusion: Despite important progress in applying personalized medicine to severe asthma, especially in T2 inflammatory phenotypes, future research is needed to find valid biomarkers predictive for the response to available biologic therapies to develop more effective therapies in non-T2 phenotype.

Sign in / Sign up

Export Citation Format

Share Document